A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
- 9 June 2020
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 181 (8) , 606-612
Abstract
Introduction: Interleukin-5 (IL-5) is the principal cytokine regulating eosinophil growth, differentiation, activation, and expression. It is a specific target of mepolizumab, an anti-IL-5 monoclonal antibody used in the treatment of severe eosinophilic asthma. This new drug can improve symptoms, reduce asthma exacerbations and steroid use. Few data are available on its efficacy for nasal symptoms. Objective: To describe the all-round clinical impact of mepolizumab in a real-life setting, evaluating the efficacy and safety of the drug in severe eosinophilic asthma patients. Population and Methods: We retrospectively collected the clinical and functional data on 27 patients (16 males) affected with severe eosinophilic asthma, diagnosed at the Siena Regional Referral Centre and monitored for 6 months. Clinical, immunological, and functional data at baseline and follow-up were entered in a database together with comorbidities, number of exacerbations, steroid treatment, multiple-flow exhaled nitric oxide, and validated questionnaires. Results: A significant reduction in asthma exacerbations was observed in all patients after 6 months of the biological therapy (p = 0.0009), and 4/6 patients discontinued chronic oral steroids. A significant improvement in ACT, FEV1, SNOT22, and alveolar nitric oxide was observed after 1 month of mepolizumab (p = 0.003, p = 0.007, p = 0.047, and p = 0.019, respectively) and maintained after 6 months of treatment. After 6 months, FeNO 50 was reduced as well (p = 0.030). Mepolizumab was very well tolerated, and no major side effects were observed. Conclusions: Our study suggests that mepolizumab is effective in improving control of asthma, lung function parameters, exhaled biomarkers, and nasal symptoms in patients with severe eosinophilic asthma.Keywords
This publication has 33 references indexed in Scilit:
- SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthmaClinical and Molecular Allergy, 2017
- Executive Summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lungEuropean Respiratory Journal, 2017
- Inducible nitric oxide synthase expression is increased in the alveolar compartment of asthmatic patientsAllergy, 2016
- French adaptation and validation of the Sino‐Nasal Outcome Test‐22: a prospective cohort study on quality of life among 422 subjectsClinical Otolaryngology, 2015
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e NO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004